RAB25, member RAS oncogene familyGenealiases: CATX-8 · RAB11C
Q-omics provides the consensus-scored RAB25 profile across patient tissues and cancer cell-line models. RAB25 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB25 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, RAB25 protein abundance shows 19,892 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where RAB25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB25 survival associations across molecular data types. RAB25 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB25 RNA expression–survival associations across cancer types. High RAB25 expression shows unfavorable associations in KIRC, SKCM, ACC, READ, PAAD and OV. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB25 RNA expression.
This table summarizes RAB25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB25 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in LUAD, BLCA and COAD. The KIRC box plot shows higher RAB25 RNA expression in normal versus tumor tissue (log2 FC = −5.687, t-test p < 0.001).
This table shows molecular features associated with RAB25 in patient tissues and cancer cell lines. In patient samples, RAB25 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
